Blood eosinophil counts as markers of response to inhaled corticosteroids in COPD?--Authors' reply.
GlaxoSmithKline, Research Triangle Park, NC 27709, USA. Electronic address: steven.j.pascoe@gsk.com.
Steven
S
Pascoe
GlaxoSmithKline, Research Triangle Park, NC 27709, USA.
Nicholas
N
Locantore
University of Alabama Lung Health Center, University of Alabama at Birmingham, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA.
Mark T
MT
Dransfield
GlaxoSmithKline, Uxbridge, Middlesex, UK; William Harvey Institute, Barts & The London School of Medicine and Dentistry, London, UK.
Neil C
NC
Barnes
Respiratory Medicine Unit, Nuffield Department of Clinical Medicine, University of Oxford, UK.
Ian
I
Pavord
D000730:Androstadienes / Q000627:therapeutic use*; D001592:Benzyl Alcohols / Q000627:therapeutic use*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D002722:Chlorobenzenes / Q000627:therapeutic use*; D004804:Eosinophils / Q000187:drug effects*; D005260:Female; D006801:Humans; D008297:Male; D029424:Pulmonary Disease, Chronic Obstructive / Q000097:blood* / Q000188:drug therapy*
D000730:Androstadienes; D001592:Benzyl Alcohols; D001993:Bronchodilator Agents; D002722:Chlorobenzenes